About CCAAT/enhancer-binding protein alpha
CCAAT/enhancer-binding protein alpha (CEBPA) is a protein
from Homo sapiens identified by UniProt accession
P49715, 358 residues long.
MolForge cross-references it against 0 known binders and
815 disease associations.
Target properties
| Protein name | CCAAT/enhancer-binding protein alpha |
| UniProt accession | P49715 |
| Gene | CEBPA |
| Organism | Homo sapiens |
| Length | 358 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (815)
Diseases linked to this target (Open Targets).
- acute myeloid leukemia · score 0.82
- erythrocyte count · score 0.45
- BMI-adjusted waist-hip ratio · score 0.44
- apolipoprotein A 1 measurement · score 0.42
- mean corpuscular volume · score 0.40
- red blood cell density measurement · score 0.40
- high density lipoprotein cholesterol measurement · score 0.40
- hereditary neoplastic syndrome · score 0.39
- Inherited cancer-predisposing syndrome · score 0.39
- basophil count · score 0.39
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P49715-F1 | alphafold | PREDICTED | 61.70 | — |
Amino-acid sequence (358 residues)
MESADFYEAE PRPPMSSHLQ SPPHAPSSAA FGFPRGAGPA QPPAPPAAPE PLGGICEHET SIDISAYIDP AAFNDEFLAD LFQHSRQQEK AKAAVGPTGG GGGGDFDYPG APAGPGGAVM PGGAHGPPPG YGCAAAGYLD GRLEPLYERV GAPALRPLVI KQEPREEDEA KQLALAGLFP YQPPPPPPPS HPHPHPPPAH LAAPHLQFQI AHCGQTTMHL QPGHPTPPPT PVPSPHPAPA LGAAGLPGPG SALKGLGAAH PDLRASGGSG AGKAKKSVDK NSNEYRVRRE RNNIAVRKSR DKAKQRNVET QQKVLELTSD NDRLRKRVEQ LSRELDTLRG IFRQLPESSL VKAMGNCA
Explore CCAAT/enhancer-binding protein alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets